

AMENDMENTS TO THE CLAIMS

1. (canceled)
2. (original) A method for the treatment of osteoporosis post-hip fracture to prevent or reduce subsequent osteoporotic skeletal fractures in a patient in need of such treatment, which method comprises administering an effective amount of a bisphosphonate to said patient, said patient having recently undergone recent repair of the hip fracture.
3. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein administration of the ~~zoledronic acid~~ bisphosphonate is within 90 days of the repair of the hip fracture.
4. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein administration of the ~~zoledronic acid~~ bisphosphonate is within 60 days of the repair of the hip fracture.
5. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein administration of the ~~zoledronic acid~~ bisphosphonate is within 42 days of the repair of the hip fracture.
6. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein administration of the ~~zoledronic acid~~ bisphosphonate is within 1-7 days of the repair of the hip fracture.
7. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein the ~~medicament~~ bisphosphonate is administered intravenously ~~for intravenous administration~~.
8. (currently amended) A ~~use according to claim 1 or~~ method according to claim ~~[[2]]~~ 18, wherein the ~~medicament~~ zoledronic acid is in unit dose form and the effective amount of the zoledronic acid is 5 mg.
9. (currently amended) A ~~use according to claim 1 or~~ method according to claim ~~[[2]]~~ 18, wherein the zoledronic acid is the free acid.
10. (currently amended) A ~~use or~~ method according to claim 5, wherein the bisphosphonate is zoledronic acid is in the free acid form.
11. (currently amended) A ~~use or~~ method according to claim 10, wherein the effective amount of the free acid is 5 mg, and wherein the effective amount is administered for administration intravenously over a 15-minute period.
12. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein the ~~zoledronic acid~~ bisphosphonate is administered intermittently such that the period between administrations of the effective amount of ~~zoledronic acid~~ the bisphosphonate is at least about 6 months.
13. (currently amended) A ~~use or~~ method according to claim 12, wherein the period between administrations is about 1 year.
14. (currently amended) A ~~use according to claim 1 or~~ method according to claim 2, wherein said patient is additionally administered vitamin D2 prior to administration of the ~~zoledronic acid~~ bisphosphonate.
15. (currently amended) A ~~use or~~ method according to claim 14, wherein the vitamin D2 is administered at least 14 days prior to administration of the ~~zoledronic acid~~ bisphosphonate.

16. (currently amended) A ~~use according to claim 1~~ or method according to claim 2, wherein the patient is additionally administered a vitamin D supplement on a daily basis.

17. (currently amended) A ~~use according to claim 1~~ or method according to claim 2, wherein the patient is additionally administered a calcium supplement on a daily basis.

18. (new) The method of claim 2 wherein the bisphosphonate is zoledronic acid.